Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on August 6, 2018. The report details a material definitive agreement entered into on the same date regarding a private placement of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock via a definitive purchase agreement.
- Purchaser: The Leukemia & Lymphoma Society, Inc.
- Total Offering Size: Up to $5.0 million in gross proceeds.
- Initial Closing (August 6, 2018):
- Shares Issued: 150,987
- Price Per Share: $6.62
- Gross Proceeds: $1.0 million
- Net Proceeds (after expenses): Approximately $0.9 million
- Future Closings: Up to four additional closings possible, contingent on achieving specified milestones. Pricing for future closings will be based on the volume-weighted average price of the stock over three trading days following milestone achievement.
- Deadline: All closings must be completed prior to December 31, 2021.
- Use of Proceeds: Funding for the Company's SOLAR clinical trial.
Material Changes
The filing reports the entry into a new financing agreement. There are no comparative financial metrics (revenue, profit, cash flow) provided in this specific 8-K filing as it focuses solely on the equity transaction. The filing does not provide a clear value for the Company's overall debt or liquidity position outside of the proceeds from this specific transaction.
Guidance, Outlook, and Risks
- Outlook: The Company expects to raise up to $5.0 million if all milestones are met and subsequent closings occur.
- Risks: Future closings are subject to the achievement of specified milestones and customary closing conditions. The filing includes standard forward-looking statement disclaimers regarding uncertainties in milestone achievement and future obligations.
- Regulatory Status: Shares were sold under exemptions from registration (Section 4(a)(2) and Rule 506 of Regulation D) and are restricted securities.
Investor Verification Checklist
- Verify the specific milestones required to trigger the remaining $4.0 million in potential funding.
- Confirm the status and timeline of the SOLAR clinical trial to assess the likelihood of milestone achievement.
- Review the full text of the Purchase Agreement (expected in the Form 10-Q for the quarter ended September 30, 2018) for detailed rights and obligations.
- Check subsequent filings for updates on the achievement of milestones and any additional closings.